5 August 2022 – Pfizer AG has submitted an application to Swissmedic to extend the marketing authorisation of its Covid-19 vaccine Comirnaty, which has been authorised since December 2020. The bivalent vaccine contains messenger ribonucleic acid (mRNA) for both the spike protein of the Wuhan strain and that of the Omicron variant. Thus, the adapted composition promises a higher efficacy against the omicron variant of SARS-CoV-2.

For more information, see here.